NEW YORK (GenomeWeb News) – Horizon Discovery said today it has received a share of a European Union Seventh Framework Programme grant totaling €5.75 million ($7.8 million) for work it will do on a project called "CV genes-at-target."

The grant was awarded to a consortium of research institutions and companies to study genomic risk loci for coronary artery disease and stroke in in vitro and in vivo settings and to determine whether they can serve as therapeutic targets.

Horizon did not specify how much of the grant it is receiving.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.